TCL Archive NCI Advisors Approve Recompetition Of $132 Million Proteomic Technologies Network March 12, 2010
TCL Archive In Brief: Weicker Joins Tobacco Company Board; Hatfield To Leave Senate Next Year December 8, 1995
TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005